

EilÃ-s Dowd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3673353/publications.pdf>

Version: 2024-02-01

62
papers

2,229
citations

159358

30
h-index

223531

46
g-index

63
all docs

63
docs citations

63
times ranked

2918
citing authors

#	ARTICLE	IF	CITATIONS
1	P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint. <i>British Journal of Pharmacology</i> , 1998, 125, 341-346.	2.7	132
2	Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. <i>Neuroscience</i> , 2011, 175, 251-261.	1.1	121
3	Further characterisation of the LPS model of Parkinson's disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. <i>Brain, Behavior, and Immunity</i> , 2013, 27, 91-100.	2.0	100
4	Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the β 2-microglobulin peptide intracellularly in hippocampal and cortical neurons. <i>Neuroscience</i> , 2004, 129, 583-592.	1.1	91
5	Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. <i>Experimental Neurology</i> , 2015, 269, 133-141.	2.0	87
6	The Corridor Task: A simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. <i>Brain Research Bulletin</i> , 2005, 68, 24-30.	1.4	86
7	Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. <i>European Journal of Neuroscience</i> , 2005, 22, 2587-2595.	1.2	84
8	Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. <i>Brain Research</i> , 2010, 1359, 33-43.	1.1	75
9	The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in situ gelling collagen hydrogel. <i>Biomaterials</i> , 2013, 34, 9420-9429.	5.7	75
10	Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. <i>Journal of Physiology</i> , 1998, 507, 843-855.	1.3	74
11	GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. <i>Neuroscience</i> , 2015, 303, 402-411.	1.1	74
12	Encapsulation of primary dopaminergic neurons in a GDNF-loaded collagen hydrogel increases their survival, re-innervation and function after intra-striatal transplantation. <i>Scientific Reports</i> , 2017, 7, 16033.	1.6	67
13	Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease. <i>Neuroscience</i> , 2008, 154, 631-640.	1.1	46
14	Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. <i>Experimental Neurology</i> , 2016, 283, 204-212.	2.0	46
15	Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats. <i>Behavioural Brain Research</i> , 2005, 159, 153-161.	1.2	45
16	Gamma Band Light Stimulation in Human Case Studies: Groundwork for Potential Alzheimer's Disease Treatment. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 171-185.	1.2	43
17	Deficits in a lateralized associative learning task in dopamine-depleted rats with functional recovery by dopamine-rich transplants. <i>European Journal of Neuroscience</i> , 2004, 20, 1953-1959.	1.2	42
18	Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 645-656.	1.4	42

#	ARTICLE	IF	CITATIONS
19	Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. <i>Brain Research Bulletin</i> , 2010, 81, 543-548.	1.4	42
20	The neurotoxicity of gene vectors and its amelioration by packaging with collagen hollow spheres. <i>Biomaterials</i> , 2013, 34, 2130-2141.	5.7	37
21	Polyhydroxyalkanoate/carbon nanotube nanocomposites: flexible electrically conducting elastomers for neural applications. <i>Nanomedicine</i> , 2016, 11, 2547-2563.	1.7	37
22	A role for viral infections in Parkinson's etiology?. <i>Neuronal Signaling</i> , 2018, 2, NS20170166.	1.7	37
23	The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. <i>Brain Research</i> , 2010, 1363, 40-48.	1.1	36
24	Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV- α -synuclein and the pesticide, rotenone. <i>Neuroscience</i> , 2012, 203, 170-179.	1.1	36
25	Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells. <i>Protein Science</i> , 2012, 21, 904-909.	3.1	34
26	Harnessing stem cells and biomaterials to promote neural repair. <i>British Journal of Pharmacology</i> , 2019, 176, 355-368.	2.7	34
27	Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. <i>Brain Research Bulletin</i> , 2008, 77, 312-319.	1.4	33
28	Heat Shock Protein 70 Reduces α -Synuclein-induced Predegenerative Neuronal Dystrophy in the α -Synuclein Viral Gene Transfer Rat Model of Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 50-58.	1.9	33
29	Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. <i>Neuroscience</i> , 2011, 181, 234-242.	1.1	32
30	GDNF Gene Delivery via a 2-(Dimethylamino)ethyl Methacrylate Based Cyclized Knot Polymer for Neuronal Cell Applications. <i>ACS Chemical Neuroscience</i> , 2013, 4, 540-546.	1.7	32
31	Fibrin-based microsphere reservoirs for delivery of neurotrophic factors to the brain. <i>Nanomedicine</i> , 2015, 10, 765-783.	1.7	32
32	Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemiparkinsonian rats. <i>European Journal of Neuroscience</i> , 2019, 49, 487-496.	1.2	30
33	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. <i>Molecules</i> , 2020, 25, 453.	1.7	30
34	Adenosine A1 receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic rat knee joint. <i>British Journal of Pharmacology</i> , 1998, 125, 1267-1271.	2.7	28
35	Untying a nanoscale knotted polymer structure to linear chains for efficient gene delivery in vitro and to the brain. <i>Nanoscale</i> , 2014, 6, 7526-7533.	2.8	28
36	The behavioural and neuropathological impact of intranigral AAV- α -synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. <i>Behavioural Brain Research</i> , 2013, 243, 6-15.	1.2	26

#	ARTICLE	IF	CITATIONS
37	Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells. <i>International Journal of Cell Biology</i> , 2010, 2010, 1-10.	1.0	25
38	Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: Restoration of bilateral food retrieval by dopamine receptor agonism. <i>Behavioural Brain Research</i> , 2006, 169, 352-355.	1.2	23
39	Movement without dopamine: striatal dopamine is required to maintain but not to perform learned actions. <i>Biochemical Society Transactions</i> , 2007, 35, 428-432.	1.6	22
40	Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2017, 310, 103-106.	1.1	20
41	The potential of biomaterials for central nervous system cellular repair. <i>Neurochemistry International</i> , 2021, 144, 104971.	1.9	20
42	Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility. <i>Behavioural Brain Research</i> , 2005, 165, 181-186.	1.2	19
43	Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS. <i>Biomaterials Science</i> , 2013, 1, 556.	2.6	19
44	Interaction between subclinical doses of the Parkinson's disease associated gene, α -synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. <i>Behavioural Brain Research</i> , 2017, 316, 160-168.	1.2	19
45	Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials. <i>European Journal of Neuroscience</i> , 2019, 49, 472-486.	1.2	18
46	Preparation of Cytocompatible ITO Neuroelectrodes with Enhanced Electrochemical Characteristics Using a Facile Anodic Oxidation Process. <i>Advanced Functional Materials</i> , 2018, 28, 1605035.	7.8	16
47	Viral mimetic priming enhances α -synuclein-induced degeneration: Implications for Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 525-535.	2.0	16
48	Targeting delivery in Parkinson's disease. <i>Drug Discovery Today</i> , 2016, 21, 1313-1320.	3.2	15
49	Brain repair for Parkinson's disease: is the answer in the matrix?. <i>Neural Regeneration Research</i> , 2018, 13, 1187.	1.6	10
50	Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?. <i>Progress in Brain Research</i> , 2012, 200, 113-142.	0.9	9
51	Fibrin As a Scaffold for Delivery of GDNF Overexpressing Stem Cells to the Adult Rat Brain. <i>ACS Biomaterials Science and Engineering</i> , 2015, 1, 559-566.	2.6	9
52	Cannabinoids in Parkinson's disease. , 2015, , 35-59.		7
53	Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease. <i>Behavioural Brain Research</i> , 2016, 296, 451-458.	1.2	7
54	Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α -Synuclein in the Rat Brain. <i>Molecules</i> , 2022, 27, 507.	1.7	6

#	ARTICLE	IF	CITATIONS
55	Anti-inflammatory cytokine-eluting collagen hydrogel reduces the host immune response to dopaminergic cell transplants in a rat model of Parkinson's disease. <i>Neuronal Signaling</i> , 2021, 5, NS20210028.	1.7	4
56	Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems. <i>Journal of Parkinson's Disease</i> , 2021, 11, S229-S236.	1.5	4
57	Human Amniocytes Regulate Serotonin Levels by Active Uptake and Express Genes Suggestive of a Wider Role in Facilitating Neurotransmitter Regulation in the Fetal Environment. <i>Stem Cells and Development</i> , 2011, 20, 341-349.	1.1	3
58	Back to the future: lessons from past viral infections and the link with Parkinson's disease. <i>Neuronal Signaling</i> , 2021, 5, NS20200051.	1.7	3
59	Central CB ₂ receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential. <i>Neural Regeneration Research</i> , 2016, 11, 1409.	1.6	3
60	The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models. <i>Biomolecules</i> , 2021, 11, 1685.	1.8	3
61	In memory of Tom Isaacs: The epitomical mover and shaker. <i>European Journal of Neuroscience</i> , 2019, 49, 303-303.	1.2	1
62	Harnessing stem cells and biomaterials to promote neural repair. <i>British Journal of Pharmacology</i> , 2019, 176, 355-368.	2.7	1